Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial

被引：0
|
作者：
Xu, Jie [1 ]
机构：
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11525
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial
    Xu, Jie
    Xie, Lu
    Sun, Xin
    Liu, Kuisheng
    Liang, Xin
    Cai, Zhenyu
    Tang, Xiaodong
    Guo, Wei
    CLINICAL CANCER RESEARCH, 2023, 29 (06) : 1040 - 1046
  • [2] Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma
    Raciborska, Anna
    Bilska, Katarzyna
    Drabko, Katarzyna
    Chaber, Radoslaw
    Pogorzala, Monika
    Wyrobek, Elzbieta
    Polczynska, Katarzyna
    Rogowska, Elzbieta
    Rodriguez-Galindo, Carlos
    Wozniak, Wojciech
    PEDIATRIC BLOOD & CANCER, 2013, 60 (10) : 1621 - 1625
  • [3] Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma
    Dogan, Izzet
    Iribas, Ayca
    Ahmed, Melin Aydan
    Basaran, Mert
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (04) : 343 - 347
  • [4] Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.
    Dogan, Izzet
    Iribas, Ayca
    Ekenel, Meltem
    Basaran, Mert
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
    Zhu, Jia
    Wang, Juan
    Sun, Feifei
    Zhen, Zijun
    Chen, Tingting
    Lu, Suying
    Huang, Junting
    Zhang, Yizhuo
    Sun, Xiaofei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS).
    Defachelles, Anne Sophie
    Bogart, Emilie
    Casanova, Michela
    Merks, Hans
    Bisogno, Gianni
    Calareso, Giuseppina
    Melcon, Soledad Gallego
    Gatz, Susanne
    Le Deley, Marie-Cecile
    McHugh, Kieran
    Probst, Alicia
    Rocourt, Nathalie
    van Rijn, Rick R.
    Wheatley, Keith
    Minard-Colin, Veronique
    Chisholm, Julia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Randomized Phase 2 Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide, in Children and Adults with Refractory or Relapsed Rhabdomyosarcoma (RMS)
    Defachelles, A. S.
    Bogart, E.
    Casanova, M.
    Merks, H.
    Bisogno, G.
    Calareso, G.
    Gallego, S.
    Gatz, S.
    Le Deley, M. C.
    Mc Hugh, K.
    Probst, A.
    Rocourt, N.
    Van Rijn, R.
    Wheatley, K.
    Minard-Colin, V.
    Chisholm, J.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S5 - S6
  • [8] Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory neuroblastoma.
    Zhu, Jia
    Zhen, Zijun
    Wang, Juan
    Chen, Tingting
    Lu, Suying
    Sun, Feifei
    Huang, Junting
    Que, Yi
    Zhang, Lian
    Zhang, Yizhuo
    Sun, Xiaofei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma
    Van Hal, Gertjan
    Rubio-San-Simon, Alba
    Ogawa, Chitose
    Juan-Ribelles, Antonio
    Knoderer, Holly
    Lewin, Jeremy Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
    Ju, Hee Young
    Park, Meerim
    Lee, Jun Ah
    Park, Hyeon Jin
    Park, Seog Yun
    Kim, June Hyuk
    Kang, Hyun Guy
    Yang, Hee Chul
    Park, Byung-Kiu
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 563 - 571
12345